You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
|
|---|---|
| Published in |
Journal of Translational Medicine, March 2017
|
| DOI | 10.1186/s12967-017-1164-1 |
| Pubmed ID | |
| Authors |
Toni Rose Jue, Kyoko Nozue, Ashleigh J. Lester, Swapna Joshi, Lisette B. W. Schroder, Shane P. Whittaker, Sheri Nixdorf, Robert W. Rapkins, Mustafa Khasraw, Kerrie L. McDonald |
| Abstract |
The O (6) -methylguanine methyltransferase (MGMT) gene is frequently unmethylated in patients with glioblastoma (GBM), rendering them non-responsive to the standard treatment regime of surgery followed by concurrent radiotherapy (RT) and temozolomide. Here, we investigate the efficacy of adding a PARP inhibitor, veliparib, to radiotherapy to treat MGMT unmethylated GBM. The inhibition of PARP with veliparib (ABT-888), a potent and orally bioavailable inhibitor in combination with RT was tested on a panel of patient derived cell lines (PDCLs) and patient-derived xenografts (PDX) models generated from GBM patients with MGMT unmethylated tumors. The combination of veliparib and RT inhibited colony formation in the majority of PDCLs tested. The PDCL, RN1 showed significantly reduced levels of the homologous repair protein, Mre11 and a heightened response to PARP inhibition measured by increased apoptosis and decreased colony formation. The oral administration of veliparib (12.5 mg/kg, twice daily for 5 days in a 28-day treatment cycle) in combination with whole brain RT (4 Gy) induced apoptosis (Tunel staining) and decreased cell proliferation (Ki67 staining) in a PDX of MGMT unmethylated GBM. Significantly longer survival times of the PDX treated with the combination treatment were recorded compared to RT only or veliparib only. Our results demonstrate preclinical efficacy of targeting PARP at multiple levels and provide a new approach for the treatment of MGMT unmethylated GBM. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 46 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 8 | 17% |
| Student > Ph. D. Student | 7 | 15% |
| Other | 5 | 11% |
| Student > Doctoral Student | 4 | 9% |
| Student > Master | 3 | 7% |
| Other | 5 | 11% |
| Unknown | 14 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 37% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Agricultural and Biological Sciences | 3 | 7% |
| Chemistry | 2 | 4% |
| Nursing and Health Professions | 1 | 2% |
| Other | 5 | 11% |
| Unknown | 15 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2017.
All research outputs
#15,164,176
of 23,322,258 outputs
Outputs from Journal of Translational Medicine
#2,039
of 4,117 outputs
Outputs of similar age
#200,738
of 334,935 outputs
Outputs of similar age from Journal of Translational Medicine
#37
of 72 outputs
Altmetric has tracked 23,322,258 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,117 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,935 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.